In animal models of AD, deficiency of CD36 prevents cerebrovascular effects and oxidative stress elicited by Aβ [79, 82], suggesting that CD36 could be a therapeutical target mainly for the treatment of neurovascular dysfunction in AD patients. The gene discussed is CD36; the disease is Alzheimer disease.